Next generation sequencing, also known as high-throughput sequencing, is a DNA sequencing technology that has revolutionized genomic research. Due to its ability to sequence DNA, NGS technologies have drawn attention in scientific research.
The global next generation sequencing market was valued at USD 4.01 billion in 2015 and is projected to reach USD 12 billion by 2021, at a CAGR of 20% during the forecast period from 2016 to 2021.
The technology is emerging at a rapid pace, due to its increasing application in clinical diagnosis. Speed, cost, and accuracy of the technology, efficient replacement of traditional technologies (microarrays), and drug discovery applications demanding NGS technology are few factors driving the growth of this market. Legal & ethical issues are likely to hamper the market growth. Interpretation of complex data and lack of skilled professionals are the other major factors restraining the NGS market growth.
The global next generation sequencing market has been segmented by –
Application: drug discovery/personalized medicine, genetic screening, diagnostics/infectious diseases, agricultural and animal research, and others.
The drug discovery/personalized medicine segment dominates the application segment. However, diagnostics/infectious diseases segment is the fastest growing of the NGS Market.
Technology: whole genome sequencing, targeted re-sequencing, whole exome sequencing, RNA sequencing, Chip sequencing, De Novo sequencing, and methyl sequencing.
RNA Sequencing accounted for the largest market revenue in 2015. However, whole genome sequencing is expected to grow at the highest CAGR during the forecast period.
Products: instruments, reagents & consumables and services.
The reagents and consumables segment had the highest market share in 2015. However, services segment is expected to grow at a high CAGR through 2021.
End-User: hospitals & healthcare institutions, academics, biotech & pharma firms, and others.
The largest share in 2015 was held by the academics segment, but the pharmaceuticals segment is expected to hold the largest share by 2021.
Geography: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
North America is currently the largest market for NGS, followed by Europe. This is due to the increased awareness about the quick return on investment and accuracy of the technology. Asia-Pacific is one of the fastest growing segments.
Many players in this market are trying to expand their product portfolio to top the global market. Few companies have adopted product innovation and new product launches as their key business strategies, to ensure their dominance in the market.
The major players operating in the NGS market are –
Illumina Inc. (U.S.)
Thermo Fisher Scientific (U.S.)
Hoffmann-La Roche Ltd (Switzerland)
Pacific Biosciences (U.S.)
Agilent Technologies (U.S.)
BGI (Beijing Genomics Institute) (China)
Qiagen (The Netherlands)
Biomatters Ltd (New Zealand)
Genomatix Software GmbH (Germany)
Key Deliverables in the Study
Market analysis for the global next generation sequencing market, with region specific assessments and competition analysis.
Market definition along with the identification of key drivers, restraints opportunities and challenges.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.
Identification and analysis of the macro and micro factors that affect the global next generation sequencing market.
Insights of the market in the regions that have the highest potential for growth and also to identify the markets that are still untapped.
Manager – Partner Relations & International Marketing
Ph: +1-214-377-1121 (US)/ +44-020-3286-9338 (UK)